These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7996980)

  • 1. Withdrawal bleeding and endometrial safety.
    Padwick M
    Lancet; 1994 Dec; 344(8938):1703-4. PubMed ID: 7996980
    [No Abstract]   [Full Text] [Related]  

  • 2. The "red queen" and endometrial hyperplasia.
    Gambrell RD
    Fertil Steril; 1994 Feb; 61(2):401-2. PubMed ID: 8299806
    [No Abstract]   [Full Text] [Related]  

  • 3. A modern approach to postmenopausal HRT: trading bleeding with safety.
    Al-Azzawi F; Wahab M
    Womens Health (Lond); 2012 Jan; 8(1):1-4. PubMed ID: 22171766
    [No Abstract]   [Full Text] [Related]  

  • 4. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a Cochrane review summary.
    Roberts H; Hickey M; Lethaby A
    Maturitas; 2014 Jan; 77(1):4-6. PubMed ID: 24182544
    [No Abstract]   [Full Text] [Related]  

  • 5. The endometrium--from estrogens alone to TSECs.
    Pickar JH
    Climacteric; 2009 Dec; 12(6):463-77. PubMed ID: 19905899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Farquhar C; Sarkis A; Roberts H; Jepson R; Barlow D
    Cochrane Database Syst Rev; 2000; (2):CD000402. PubMed ID: 10796715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further evidence for promoting transdermal estrogens in the management of postmenopausal symptoms.
    Canonico M; Scarabin PY
    Menopause; 2011 Oct; 18(10):1038-9. PubMed ID: 21946050
    [No Abstract]   [Full Text] [Related]  

  • 8. Steroids and endometrial breakthrough bleeding. Proceedings of a meeting. Melbourne, Australia, 4-5 May 1999.
    Hum Reprod; 2000 Aug; 15 Suppl 3():i-ii, 1-207. PubMed ID: 11228650
    [No Abstract]   [Full Text] [Related]  

  • 9. Transdermal and vaginal estradiol for the treatment of menopausal symptoms: the nuts and bolts.
    Kaunitz AM
    Menopause; 2012 Jun; 19(6):602-3. PubMed ID: 22549171
    [No Abstract]   [Full Text] [Related]  

  • 10. The new hormone therapy problem: do we solve it with long-cycle progesterone therapy?
    Ravnikar V
    Menopause; 2005; 12(6):664-7. PubMed ID: 16278608
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension.
    Sriprasert I; Beydoun H; Barnabei V; Nassir R; LaCroix AZ; Archer DF
    Menopause; 2015 Oct; 22(10):1067-75. PubMed ID: 25756697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen replacement therapy and endometrial hyperplasia.
    Tsang P
    JAMA; 1996 Jun; 275(24):1880-1. PubMed ID: 8648861
    [No Abstract]   [Full Text] [Related]  

  • 13. Endometrial hyperplasia following estrogen treatment without the addition of gestagen. A follow-up study after withdrawal of estrogens.
    Lindahl B; Willén R
    Anticancer Res; 1991; 11(6):2071-3. PubMed ID: 1776842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy: estrogen after menopause.
    Gibaldi M
    Pharmacotherapy; 1996; 16(3):366-75. PubMed ID: 8726594
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of breast cancer among users of estrogen plus progestogen and unopposed estrogen: is the likelihood of bias symmetrical?
    Shapiro S
    Climacteric; 2015 Jun; 18(3):333-5. PubMed ID: 25651904
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hormone replacement: side effects and problems].
    Kueng F
    Ther Umsch; 2000 Oct; 57(10):643-5. PubMed ID: 11081376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.
    Doherty JA; Cushing-Haugen KL; Saltzman BS; Voigt LF; Hill DA; Beresford SA; Chen C; Weiss NS
    Am J Obstet Gynecol; 2007 Aug; 197(2):139.e1-7. PubMed ID: 17689625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HRT in post-menopausal women: endometrial histology and bleeding patterns].
    Lo Dico G; Alongi G; Spinelli MP; Cannariato P; Lucido AM
    Minerva Ginecol; 2002 Aug; 54(4):361-6. PubMed ID: 12114870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen replacement therapy and risk of ovarian cancer.
    Noller KL
    JAMA; 2002 Jul; 288(3):368-9. PubMed ID: 12117404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.